Apelian, S.; Martincuks, A.; Whittum, M.; Yasukawa, M.; Nguy, L.; Mathyk, B.; Andikyan, V.; Anderson, M.L.; Rutherford, T.; Cristea, M.;
et al. PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies. Biomedicines 2025, 13, 1126.
https://doi.org/10.3390/biomedicines13051126
AMA Style
Apelian S, Martincuks A, Whittum M, Yasukawa M, Nguy L, Mathyk B, Andikyan V, Anderson ML, Rutherford T, Cristea M,
et al. PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies. Biomedicines. 2025; 13(5):1126.
https://doi.org/10.3390/biomedicines13051126
Chicago/Turabian Style
Apelian, Shant, Antons Martincuks, Michelle Whittum, Maya Yasukawa, Lindsey Nguy, Begum Mathyk, Vaagn Andikyan, Matthew L. Anderson, Thomas Rutherford, Mihaela Cristea,
and et al. 2025. "PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies" Biomedicines 13, no. 5: 1126.
https://doi.org/10.3390/biomedicines13051126
APA Style
Apelian, S., Martincuks, A., Whittum, M., Yasukawa, M., Nguy, L., Mathyk, B., Andikyan, V., Anderson, M. L., Rutherford, T., Cristea, M., Stewart, D., & Kohut, A.
(2025). PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies. Biomedicines, 13(5), 1126.
https://doi.org/10.3390/biomedicines13051126
